20:23 , Feb 23, 2018 |  BC Week In Review  |  Company News

Voyager, AbbVie to develop anti-tau gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) partnered with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat Alzheimer's disease and other tauopathies. Using Voyager's adeno-associated...
22:35 , Feb 20, 2018 |  BC Extra  |  Company News

Voyager, AbbVie partner for AD gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) jumped $4.30 (22%) to $23.66 on Tuesday after partnering with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat...
21:08 , May 25, 2017 |  BC Extra  |  Company News

Merck obtains rights to Teijin's tau candidate

Teijin Pharma Ltd. (Tokyo, Japan) granted Merck & Co. Inc. (NYSE:MRK) exclusive rights to an undisclosed preclinical antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17). Merck plans to develop the candidate to treat Alzheimer’s disease....
22:14 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

ABBV-8E12: Ph II started

AbbVie began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate IV ABBV-8E12 in about 180 patients. AbbVie has exclusive, worldwide rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

ABBV-8E12: Ph II started

AbbVie began a double-blind, placebo-controlled, international Phase II trial to evaluate IV ABBV-8E12 in about 400 patients. AbbVie has exclusive, worldwide rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc. ’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Effectorless efficacy

In a finding that might solve the problem of dose-limiting side effects for using antibodies in CNS disorders, a Genentech-led team has engineered an anti-tau antibody for Alzheimer's disease that binds its target in the...
00:59 , Oct 15, 2015 |  BC Extra  |  Clinical News

CurePSP program recruits patients for AbbVie, BMS trials

Non-profit CurePSP (Timonium, Md.) said it formed the Patient Engagement Program to assist in patient recruitment for clinical trials to treat degenerative brain diseases including progressive supranuclear palsy (PSP). CurePSP said it agreed with AbbVie...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

C2N-8E12: Phase I started

C2N began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV C2N-8E12 in about 32 patients. FDA also granted Orphan Drug designation to the product for PSP. AbbVie has exclusive,...